Metabolic Tracers for Kidney Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor growth. This study uses specially labeled nutrient tracers of compounds normally found circulating in the blood. The nutrients (glucose, fructose, glutamine, acetate, and lactate) are also found in common foods. A nutrient tracer will be given to the participants through an intravenous (IV) catheter during surgery or biopsy, and blood will be collected every 30 minutes during the infusion to monitor safety parameters and the nutrient tracers. The investigators will collect a tissue sample after the completion of surgery. Participants not having an infusion will have their tissue collected after surgery or biopsy.Participation in this study will not change patient care. All patients will receive standard of care treatment as determined by their doctors.
Do I need to stop my current medications for this trial?
The trial does not specify if you need to stop taking your current medications. It mentions that participation will not change your standard care, so it's likely you can continue your medications, but you should confirm with the trial team.
Is the use of 13C-labeled metabolic tracers safe for humans?
How does the treatment using metabolic tracers for kidney cancer differ from other treatments?
This treatment is unique because it uses hyperpolarized 13C pyruvate magnetic resonance imaging to non-invasively differentiate between benign and malignant kidney tumors by analyzing their metabolic activity, specifically lactate production, which is not possible with conventional imaging methods.12567
What data supports the effectiveness of the treatment 13C-Acetate and other Carbon-13 labeled compounds for kidney cancer?
The research does not provide direct evidence supporting the effectiveness of 13C-Acetate or other Carbon-13 labeled compounds for treating kidney cancer. However, studies show that metabolic imaging using hyperpolarized 13C-pyruvate can differentiate between aggressive and less aggressive kidney tumors, suggesting that metabolic tracers can be useful in understanding tumor behavior.12589
Who Is on the Research Team?
Vitaly Margulis
Principal Investigator
University of Texas Southwestern Medical Center
Are You a Good Fit for This Trial?
Adults with probable or confirmed kidney or urothelial cancer needing surgery can join. They must understand and sign consent, and may be in other trials if approved by the lead doctor. Not for those with uncontrolled diabetes (if getting a tracer infusion), pregnant/breastfeeding women, or non-surgical candidates.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Surgery/Biopsy and Infusion
Participants undergo surgical resection or biopsy with infusion of 13C-labeled nutrient tracers and blood collection every 30 minutes during the procedure
Follow-up
Participants are monitored for safety and effectiveness after the procedure
What Are the Treatments Tested in This Trial?
Interventions
- 13C-Acetate
- 13C-Fructose
- 13C-Glucose
- 13C-Glutamine
- 13C-Lactate
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Howard Hughes Medical Institute
Collaborator